Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2021

View Archived Issues

KRAS just wants to help: Pancreatic KRAS mutations may be protection gone bad

CNGA1 behind retinal degeneration, murine model shows

Guanylate cyclase C agonist IW-3300 shows promise for treating visceral pain

Mitokinin discloses PINK1 activators

Bahcesehir Universitesi presents Hdm2 inhibitors

Achillion Pharmaceuticals identifies new complement factor D inhibitors

UCL Business describes new CRP inhibitors

Nanjing Sanhome Pharmaceutical divulges anti-CD47/anti-PD-L1 antibodies

Novel potent TGR5 agonist shows antidiabetic effects in TGR5(H88Y) mutant mice

VU-6028418 reverses cataleptic behavior in rat models

Endeavor BioMedicines licenses rights to ULK1/2 inhibitor for LKB1- and RAS-mutated cancers

Targeting PANX1/IL-33 axis decreases MRSA infection-induced liver damage

RARG rs2229774 genetic variant identifies cardioprotective therapy

Bantam completes seed funding to advance BTM-3566 toward the clinic

Tarveda and SciClone enter license agreement for preclinical PI3K miniature drug conjugates

Targeting RON short form suppresses breast cancer metastasis through subverted immunosuppression

Clarus licenses rights to McGill technology to treat conditions associated with CoQ10 deficiencies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...